Summary This study was undertaken to examine the relationship between circulating matrix metalloproteinase (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in our patients with either advanced small-cell lung cancer (SCLC) or nonsmall-cell lung cancer (NSCLC) prior to treatment. Thirty-one male and female patients with either stage III or IV NSCLC and 17 with either stage III or IV SCLC were compared to 117 age matched non-smoking controls of both sexes. Prior to any treatment of the patient, a baseline serum sample was obtained from each of the patients for the determination of circulating MMP-9 and TIMP-1 by ELISA. The results indicate that both MMP-9 and TIMP-1 are elevated in the serum of lung cancer patients when compared to the controls. This observation was true for both SCLC and NSCLC. However, the mean values for both MMP-9 and TIMP-1 in the two tumors were not different from each other. The natural physiological relationship between MMP-9 and the inhibitor TIMP-1 was lost in both SCLC and NSCLC, indicative of abnormal alterations by the tumor. The data from this study suggests that advanced lung cancer does alter the normal circulatory pattern of MMP-9 and TIMP-1. This could aid in the processes of tumor invasion and/or metastasis.
Introduction
It has been well established that the breakdown process involving the extracellular matrix (ECM), surrounding various cells in the body is controlled in large part by the interplay of numerous stimuli. One major stimulus of this process in part regulated by the urokinase plasminogen activator (uPA) is the collection of proteolytic enzymes known as the metalloproteinases. These metalloproteinases target the various substrates of the ECM, causing their dissolution. These proteolytic enzymes target among others the collagens, gelatin, elastin, fibrin, and proteoglycans that comprise the normal ECM. This process has also been shown to be active in tumor cells as well. 1, 2 The pharmacologic inhibition of the matrix metalloproteinases (MMPs) in cancer therapy has also been advocated as a method to prevent or impede the invasion and metastasis process of the tumor. 2 The known role of the MMPs and their inhibitors, the tissue inhibitor of matrix metalloproteinases (TIMPs), in tumor metastasis has recently been reviewed. 3 In lung cancer, most of the reported studies have been on histological specimens taken from biopsy or surgical resection, and includes both non-smallcell lung cancer (NSCLC) and small-cell lung cancer (SCLC). These reports suggest that over-expression of the metalloproteinases is a common occurrence in lung cancer cells in vitro and may play a pivotal role in the spread of the tumor. [4] [5] [6] [7] [8] When a major MMP, MMP-9, was examined in tissue culture and conjointly up-regulated by the epidermal growth factor receptor, the results indicated a poor prognosis in patients with NSCLC. 7 Much less is known about either circulating MMPs or the TIMPs in those patients with lung cancer. Thus we have elected to determine serum MMP-9 and its inhibitor, TIMP-1 in our patients with either advanced SCLC or NSCLC before any treatment modality and then compared to normal controls.
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Patients and methods
Patients
Adult patients of both genders with pathologically verified lung cancer, either small-cell or non-smallcell, who were admitted to this study, were seen at the Thoracic Oncology Clinic at the Southwest Cancer Center. Following informed consent, a Texas Tech Health Science Center Institutional Review Board for Human Subjects approved study, and prior to any treatment modality, baseline serum samples were obtained from each patient. In all, 17 patients with either stage III or IV SCLC and 31 patients with stage III or IV NSCLC were enrolled. All lung cancer patients had a history of smoking. In addition, 117 normal adult non-smoking volunteers of both sexes, greater that 40 years of age, and all involved in health care provision had blood collected to serve as the normal controls. The demographic characteristics of the lung cancer patients are summarized in Table 1 .
Analysis
The serum content of both circulating MMP-9 and TIMP-1 were determined by a monoclonal antibody based sandwich ELISA utilizing commercially available kits obtained from R&D Systems, Minneapolis, MN.
Statistics
The data was analyzed by several methodologies utilizing the INSTAT program from Graph Pad, San Diego CA. As patients with cancer cannot be expected to follow the normal distribution curve, non-parametric testing was utilized. When lung cancer patients were compared to the controls, or the SCLC to the NSCLC patients, the non-parametric Mann-Whitney t-test was used. Individual patient relationships between MMP-9 and TIMP-1 in each group of lung cancer patients were determined by non-parametric correlation analysis (Spearmans correlation), while Pearson's parametric linear correlation was used in the controls. All significance levels were at the Po0:05 or greater for two-tailed tests.
Results
To evaluate whether gender would skew the data in the lung cancer patients, this aspect was broken down by tumor histology as is evidenced in Table 2 . There was no significant difference in MMP-9 or TIMP-1 when males were compared to females in either SCLC or NSCLC. However, both male and female patients with either SCLC or NSCLC had significantly elevated MMP-9 and TIMP-1 when compared to the controls.
To further evaluate any possible relationships between MMP-9 and TIMP-1 by gender and histology, correlation analysis was also performed. The respective P values of these comparisons were SCLC males 0.9, SCLC females 0.4, NSCLC males 0.8, and NSCLC females 0.08. Therefore, the highly significant relationship in the control patients between MMP-9 and TIMP-1 (0.01) is lost in both the gender and cell type examination. As the resultant data from Table 2 indicated no difference between SCLC and NSCLC for either MMP-9 or TIMP-1 according to the sex of the patient, the results were then re-examined by stage of the tumor; which is detailed in Table 3 .
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As can be seen, when compared to the controls, with the exception of MMP-9 in stage III disease, the mean values were significantly higher than the controls in stage III TIMP-1, and stage IV for both MMP-9 and TIMP-1. Again there was no correlation between MMP-9 and TIMP-1 in either stage III or stage IV. The mean MMP-9 in stage IV lung cancer was markedly elevated over that of stage III. Also, the values for stage IV were uniformly greater than those found in stage III.
As there was no significant difference between the means of MMP-9 or TIMP-1 by gender, the data were combined and examined by tumor histology regardless of the stage. The combined gender mean values for both MMP-9 and TIMP-1 in the patients with either SCLC or NSCLC can be seen in Table 4 .
Compared to the controls, both SCLC and NSCLC induced a statistically significant increase in the mean for both MMP-9 and TIMP-1. There was no difference however in the means of either MMP-9 or TIMP-1 in SCLC vs. that of NSCLC. Mean7SD, ng/mL (P between males and females). Mean7SD, ng/ml. Table 5 reflects the examination of the data when all the SCLC and NSCLC results were combined together without regard to gender or stage. Both MMP-9 and TIMP-1 were again extremely elevated compared to the controls.
Discussion
Lung cancer is the leading cause of cancer mortality in the world and has a very poor prognosis. As uPA has been suggested to upregulate, the MMPs have been directly linked to the process of tumor invasion and metastasis, 9 the role of this family of enzymes and their inhibitors in this context has received a lot of interest recently.
Resected stage I-III tissue from NSCLC patients using immunohistochemical methods was undertaken retrospectively. 10 High tumor cell expression of MMP-9 indicated a poorer outcome, which suggested potentially prognostic information and the need for development of MMP inhibitors for cancer therapy. Further examination of lung adenocarcinoma found that both MMP-3 and MMP-10 were expressed in close proximity to the area of the ECM adjacent to the tumor blood vessels, which should aid in angiogenesis. It was also noted that expression of MMP-9 might be associated with in situ tumor progression, invasion at the microvascular level, as well as metastasis.
11
Several studies investigating the circulating levels of the MMPs and/or TIMPs have recently appeared as well. A small study, 12 with 19 patients with both small-cell and NSCLC and 23 controls found elevated MMP-9 in the serum compared to the controls. We also noted this elevation in a much larger population (Table 4 ). They also reported that the MMP-9 levels were 3.6 times higher in the cancer patients compared to controls while we saw an approximate doubling for both MMP-9 and TIMP-1. However, they did not consider this large increase a reflection of MMP-9 over-production by the tumor cells, yet did not offer any suggestion as to where the MMP-9 originated. We feel that perhaps as Kwaan has suggested, 9 the circulating uPA is activating the MMPs found in the ECM, resulting in the release of the MMPs into the circulation during this ECM breakdown process.
Stage II NSCLC was investigated in 44 patients and a significant elevation was noted in MMP-1, 2, 9, and TIMP-1 and 2.
13 This is in agreement with our findings in both advanced NSCLC and SCLC. These authors also reported the co-expression of these factors is significant. We did not find this to be true when comparing the statistical correlation of MMP-9 to TIMP-1 in our patients, which was not associated.
When 90 lung cancer patients with either squamous cell or stage III NSCLC were compared to 20 controls, TIMP-1 levels were elevated in the sera of the cancer patients, and the extremely high TIMP-1 indicated a poor prognosis.
14 Likewise, high MMP-9 was also indicative of a less than 1-year survival potential. These authors also suggested that both MMP-9 and TIMP-1 might be of value in monitoring various treatment modalities. We are currently evaluating this aspect.
The data arising from our study with a much larger control population and including both smallcell and NSCLC adds weight to the evidence that both circulating MMP-9 and TIMP-1 are elevated in these patients. As no mean significant difference was found between the two histological types of tumor for either MMP-9 or TIMP-1, yet both were extremely elevated over control values, it suggests that both tumors equally reflect the pathological changes occurring in the tumor in respect to MMP-9 and TIMP-1. The lack of correlation observed between MMP-9 and TIMP-1 in both SCLC and NSCLC patients suggest that the mechanisms that maintain homeostatic balance between activator and inhibitor, as seen in the controls, is lost. This would have a significant impact on the potential for invasion and metastasis in the cancer patient, via uncontrolled ECM breakdown. As both MMP-9 and TIMP-1 increased, it would suggest that the patients with lung cancer are trying to inhibit the increased activity of the protease via increased secretion of TIMP-1. This inhibition is apparently ineffective due to the aggressive invasive nature of these tumors. The independent action of these two factors (loss of regulation), might also be reflective of the large deviation seen, as some patients were near the norm and others extremely elevated. In our patients, 38% had elevated MMP-9, and 54% had elevated TIMP-1. This would further tend to support the suggestion that evaluation of circulating MMP-9 and TIMP-1 might indicate those patients at greater risk or who might have a poorer prognosis. It is apparent that both MMP-9 and TIMP-1 in the serum of patients with either SCLC or NSCLC are reflective of the pathological changes that are occurring in the lung. It is now time to examine these factors in all stages of the disease, as well as before and following palliative treatment to assess both morbidity and mortality rates.
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